ProMIS Neurosciences (PMN) Assets Average (2022 - 2026)
ProMIS Neurosciences' (PMN) quarterly Assets Average came in at $38.3 million in Q1 2026, up 135.25% YoY from $16.3 million in Q1 2025, and up 149.98% on a QoQ basis from $15.3 million in Q4 2025.
ProMIS Neurosciences (PMN) Assets Average (2022 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 5 years of Assets Average data on file, last reported at $38.3 million in Q1 2026.
- Quarterly Assets Average rose 135.25% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.3 million (up 135.25% YoY) and the FY2025 annual result came in at $14.0 million, down 13.64% from the prior year.
- Assets Average climbed to $38.3 million in Q1 2026, from $15.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $38.3 million in Q1 2026 to a low of $2.5 million in Q2 2024.
- A 5-year average of $12.7 million and a median of $11.6 million in 2025 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 367.06% in 2025, down 29.44% in 2025.
- Tracing PMN's Assets Average over 5 years: stood at $6.2 million in 2022, then soared by 155.93% to $15.7 million in 2023, then soared by 37.87% to $21.7 million in 2024, then slipped by 29.44% to $15.3 million in 2025, then soared by 149.98% to $38.3 million in 2026.
- The last three Assets Average figures came in at $38.3 million (Q1 2026), $15.3 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 19.82 Bn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | 62.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.05 Mn |
| Mar 31, 2026 | 38.30 Mn |
| Dec 31, 2025 | 15.32 Mn |
| Sep 30, 2025 | 15.48 Mn |
| Jun 30, 2025 | 11.58 Mn |
| Mar 31, 2025 | 16.28 Mn |
| Dec 31, 2024 | 21.71 Mn |
| Sep 30, 2024 | 12.96 Mn |
| Jun 30, 2024 | 2.48 Mn |
| Mar 31, 2024 | 8.58 Mn |
| Dec 31, 2023 | 15.75 Mn |
| Sep 30, 2023 | 9.69 Mn |
| Jun 30, 2023 | 2.96 Mn |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | 6.15 Mn |
| Sep 30, 2022 | 7.79 Mn |